Metabolism of dextromethorphan in vitro: Involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 3, 1997, Pages 227-240

  Schmider, Jürgen ^a   Greenblatt, David J ^a   Fogelman, Steven M ^a   Von Moltke, Lisa L ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 methoxymorphinan; cytochrome P450; dextromethorphan; dextrorphan; human liver microsomes; in vitro

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; DEXTROMETHORPHAN; DRUG METABOLITE; QUINIDINE; SULFAPHENAZOLE;

ARTICLE; DEMETHYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM;

ANIMALS; ANTITUSSIVE AGENTS; BENZOFLAVONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DITIOCARB; ENZYME INHIBITORS; HUMANS; METHYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; QUINIDINE; RATS; SULFAPHENAZOLE; TISSUE DONORS;

EID: 0030889604     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199704)18:3<227::AID-BDD18>3.0.CO;2-L     Document Type: Article

References (45)

1. J. W. Beinhart, The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol. Appl. Pharmacol., 55, 43-48 (1980).
2. G. Pfaff, P. Briegel and I. Lamprecht, Inter-individual variation in the metabolism of dextromethorphan. Int. J. Clin. Pharmacol., 14, 173-189 (1983).
3. D. Larrey, G. Amouyal, M. Tinel, P. Letteron, A. Berson, G. Labbe and D. Pessayre, Polymorphism of dextromethorphan oxidation in a French population. Br. J. Clin. Pharmacol., 24, 676-679 (1987).
4. B. Schmid, J. Bircher, R. Preisig and A. Küpfer, Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin. Pharmacol. Ther., 38, 618-624 (1985).
5. A. Küpfer, B. Schmid and G. Pfaff, Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica, 16, 421-433 (1986).
6. O. Mortimer, B. Lindstrom, H. Laurell, U. Bergman and A. Rane, Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br. J. Clin. Pharmacol., 27, 223-227 (1989).
7. P. Dayer, J. Desmeules, T. Leemann and R. Striberni, Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem. Biophys. Res. Commun., 152, 411-416 (1988).
8. O. Mortimer, K. Persson, M. G. Ladona, D. Spalding, U. M. Zanger, U. Mayer and A. Rane, Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan. Relationship to the presence of immunoidentified cytochrome P-450 IID1. Clin. Pharmacol. Ther., 47, 27-35 (1990).
9. P. Baumann, J. W. Meyer, M. Amey, D. Baettig, C. Bryois, M. Jonzier-Perey, L. Koeb, C. Monney and B. Woggon, Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit., 14, 1-8 (1992).
10. U. Breyer-Pfaff, B. Pfandl, K. Nill, E. Nusser, C. Monney, M. Jonzier-Perey, D. Baettig and P. Baumann, Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin. Pharmacol. Ther., 52: 350-358 (1992).
11. R. J. Guttendorf, P. J. Wedlund, J. Blake and S. L. Chang, Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism. Ther. Drug Monit., 10, 490-498 (1988).
12. E. Jacqz-Aigrain, C. Funck-Brentano and T. Cresteil, CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197-204 (1993).
13. S. V. Otton, D. Wu, R. T. Joffe, S. W. Cheung and E. M. Sellers, Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther., 53, 401-409 (1993).
14. S. H. Preskorn, J. Alderman, M. Chung, W. Harrison, M. Messig and S. Harris, Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol., 14, 90-98 (1994).
15. D. Wu, S. V. Otton, B. A. Sproule, U. Busto, T. Inaba, W. Kalow and E. M. Sellers, Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br. J. Clin. Pharmacol., 35, 30-34 (1993).
16. T. Leemann, C. Transon and P. Dayer, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci., 52, 29-34 (1993).
17. N. L. Kerry, A. A. Somogyi, F. Bochner and G. Mikus, The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br. J. Clin. Pharmacol., 38, 243-248 (1994).
18. J. C. Gorski, D. R. Jones, S. A. Wrighton and S. D. Hall, Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol., 48, 173-182 (1994).
19. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz and R. I. Shader, Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O-and N-demethylation. Br. J. Clin. Pharmacol., 41, 339-343 (1996).
20. P. D. Kroboth, M. M. Folan, R. M. Lush, P. C. Chaikin, U. A. Shukla, R. Barbhaiya and D. E. Salazar, Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J. Clin. Psychopharmacol., 15, 306-319 (1995).
21. R. H. Barbhaiya, U. A. Shukla, P. D. Kroboth and D. S. Greene, Coadministration of nefazodone and benzodiazepines: II. Pharmacokinetic interaction study with triazolam. J. Clin. Psychopharmacol., 15, 320-326 (1995).
22. D. S. Greene, D. E. Salazar, R. C. Dockens, P. Kroboth and R. H. Barbhaiya, Coadministration of nefazodone and benzodiazepines: III. Pharmacokinetic interaction study with alprazolam. J. Clin. Psychopharmacol., 15, 399-408 (1995).
23. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz and R. I. Shader, N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther., 275, 592-597 (1995).
24. L. L. von Moltke, D. J. Greenblatt, J. S. Harmatz and R. I. Shader, Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology, 47, 268-276 (1993).
25. L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, S. X. Duan, J. S. Harmatz and R. I. Shader, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther., 268, 1278-1283 (1994).
26. L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, J. S. Harmatz and R. I. Shader, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol., 38, 23-31 (1994).
27. M. Halvorson, D. Greenway, D. Eberhart, K. Fitzgerald and A. Parkinson, Reconstitution of testosterone oxidation by purified rat cytochrome P450p (IIIA1). Arch. Biochem. Biophys., 277, 166-180 (1990).
28. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. X. Duan, D. Karsov and R. I. Shader, Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology, 52, 125-134 (1996).
29. J. Norby, S. Rubenstein, T. Tuerke, S. Farmer, R. Forood and J. Bennington, SigmaPlot, Version 4.13, Jandel, 1991.
30. D. J. Newton, R. W. Wang and A. Y. H. Lu, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Disposit., 23, 154-158 (1995).
31. L. L. von Moltke, D. J. Greenblatt, J. S. Harmatz, S. X. Duan, L. M. Harrel, M. M. Cotreau-Bibbo, G. A. Pritchard, C. E. Wright and R. I. Shader, Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther., 276, 370-379 (1996).
32. L. L. von Moltke, D. J. Greenblatt, M. H. Court, S. X. Duan, J. S. Harmatz and R. I. Shader, Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin-reuptake-inhibitor antidepressants. J. Clin. Psychopharmacol., 15, 125-131 (1995).
33. J. Schmider, D. J. Greenblatt, J. S. Harmatz and R. I. Shader, Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br. J. Clin. Pharmacol., 41, 593-604 (1996).
34. G. E. Schwab, J. L. Raucy and E. F. Johnson, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol. Pharmacol., 33, 493-499 (1988).
35. T. Andersson, J. O. Miners, M. E. Veronese and D. J. Birkett, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br. J. Clin. Pharmacol., 38, 131-137 (1994).
36. M. Shou, J. Grogan, J. A. Mancewicz, K. W. Krausz, F. J. Gonzalez, H. V. Gelboin and K. R. Korzekwa, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33, 6450-6455 (1994).
37. T. K. Chang, F. J. Gonzalez and D. J. Waxman, Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 311, 437-442 (1994)
38. S. E. Clarke, S. J. Baldwin, J. C. Bloomer, A. D. Ayrton, R. S. Sozio and R. J. Chenery, Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem. Res. Toxicol., 7, 836-842 (1994).
39. W. Tassaneeyakul, M. E. Veronese, D. J. Birkett, F. J. Gonzalez and J. O. Miners, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol., 46, 1975-1981 (1993).
40. E. D. Kharasch and K. E. Thummel, Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology, 79, 795-807 (1993).
41. P. M. Bokesch, J. E. Marchand, C. S. Connelly, W. H. Wurm and R. M. Kream, Dextromethorphan inhibits ischemia-induced c-fos expression and delayed neuronal death in hippocampal neurons. Anesthesiology, 81, 470-477 (1994).
42. G. Trube and R. Netzer, Dextromethorphan: cellular effects reducing neuronal hyperactivity. Epilepsia, 35, S62-S67 (1994).
43. W. Löscher and D. Honack, Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. Eur. J. Pharmacol., 238, 191-200 (1993).
44. F. C. Tortella, J. W. Ferkany and M. J. Pontecorvo, Anticonvulsant effects of dextrorphan in rats: possible involvement in dextromethorphan-induced seizure protection. Life Sci., 42, 2509-2514 (1988).
45. M. A. Rogawski and R. J. Porter, Antiepileptic drugs: pharmacological mechanisms and clincal efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev., 42, 223-286 (1990).